GRCE

Grace Therapeutics, Inc. (GRCE) SWOT Analysis Analysis (2026)

Invetso Score: 3.1/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Strengths

Score: 4.2 (Moderate)

Liquidity is exceptionally strong with a 11.5x current and quick ratio, giving GRCE more short-term flexibility than most peers despite weak profitability.

Net debt to EBITDA of 0.54x indicates modest leverage, so balance-sheet risk is lower than for more indebted peers and supports operating resilience.

Cash conversion cycle of zero suggests working-capital discipline, which can preserve liquidity and reduce financing needs relative to peers with longer cycles.

Weaknesses

Score:

ROIC of -48.8% shows capital is destroying value, leaving GRCE structurally weaker than profitable peers on the core measure of long-term economic returns.

The absence of reported operating and gross margins limits evidence of pricing power, while peers with positive margins likely have clearer earnings durability.

High liquidity appears to reflect underutilized capital rather than operating strength, so peers with better asset productivity can compound value more effectively.

Opportunities

Score:

If management converts excess liquidity into higher-return assets, GRCE could narrow the gap with peers by improving capital efficiency and earnings quality.

Low leverage leaves room to fund restructuring or selective growth without stressing the balance sheet, unlike more constrained peers.

A zero cash conversion cycle provides a base for scaling operations efficiently if demand improves, potentially lifting peer-relative working-capital performance.

Threats

Score:

Persistently negative ROIC threatens competitive positioning because peers with positive returns can reinvest more aggressively and widen the performance gap.

If liquidity remains idle, the company may continue to lag peers on asset productivity, depressing valuation and limiting strategic flexibility.

Limited margin disclosure raises the risk that underlying profitability is structurally weak, which would leave GRCE vulnerable to peers with stronger cost structures.

Overall Score

Score:

GRCE’s balance sheet is liquid and lightly levered, but deeply negative ROIC and limited profitability evidence leave its structural positioning below most peers.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Grace Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →